Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate in COVID-19 (FENOC)
NCT04661930Phase 3Unknown
- Start
- Jan 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenofibrate in coronavirus disease 2019 (COVID-19) (3 arms). Primary endpoints: Number of Therapeutic Oxygen-Free Days at 14 days, Length of Hospital Stay at 14 days and 10 more. Status: unknown.
02
Drugs
fenofibrate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04661930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661930.